文献速递脊柱关节炎

Filgotinib减轻强直性脊柱炎椎体与后外侧脊柱炎症:TORTUGA试验结果

Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

TORTUGA试验的事后分析纳入活动性强直性脊柱炎患者,filgotinib 200 mg组58例、安慰剂组58例治疗12周,评估脊柱MRI的CANDEN评分变化。结果显示filgotinib较安慰剂显著降低总脊柱炎症评分及多数炎症亚评分,包括椎体、小关节和后外侧结构,但脂肪病变、骨侵蚀和新骨形成无显著差异。

要点

  • Filgotinib较安慰剂显著降低总脊柱炎症评分及椎体、小关节、后外侧结构炎症亚评分。
  • 角椎体和非角椎体炎症亚评分、脂肪病变、骨侵蚀及新骨形成无显著差异。
  • filgotinib组总炎症评分变化与SPARCC脊柱评分正相关,基线NBF与BASMI相关。

核心结论

  • 与安慰剂相比,filgotinib治疗与脊柱炎症MRI指标显著降低相关,包括椎体、小关节和后外侧结构。

研究设计与样本

  • TORTUGA试验的事后分析,活动性AS患者接受filgotinib 200 mg(n=58)或安慰剂(n=58)每日一次治疗12周。
  • 采用Canada-Denmark(CANDEN)MRI评分系统评估基线至第12周总脊柱及炎症、脂肪、骨侵蚀和新骨形成(NBF)亚评分变化。
  • 实际评估MRI的患者为filgotinib组47例、安慰剂组41例。

主要发现

  • filgotinib较安慰剂显著降低总脊柱炎症评分及多数炎症亚评分,包括后外侧元素(肋椎关节、横突/棘突、软组织)、小关节和椎体。
  • 角椎体或非角椎体炎症亚评分、脊柱脂肪病变、骨侵蚀或NBF评分未见显著差异。
  • filgotinib组总炎症评分自基线变化与SPARCC脊柱评分呈正相关。
  • 基线NBF评分与基线BASMI相关,但与BASFI不相关。

关键数值与推荐

  • filgotinib 200 mg每日一次,安慰剂对照,治疗12周。
  • CANDEN MRI评分系统用于评估总脊柱及分解剖部位的炎症、脂肪、骨侵蚀和NBF变化。
  • SPARCC MRI评分用于相关性分析。

临床怎么用

  • 对于活动性AS患者,filgotinib可能有助于减轻椎体、小关节和后外侧结构的脊柱炎症。
  • MRI炎症改善与SPARCC评分变化相关,支持影像学炎症评估的一致性。
  • 基线NBF与BASMI相关,提示结构损伤与脊柱活动度相关。

局限性

  • 为TORTUGA试验的事后分析,实际评估MRI的样本量小于随机分组人数。
  • 仅评估12周治疗期间的变化,未报告长期结构结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the effects of filgotinib on inflammatory and structural changes at various spinal locations, based on MRI measures in patients with active AS in the TORTUGA trial. METHODS: In the TORTUGA trial, patients with AS received filgotinib 200 mg (n = 58) or placebo (n = 58) once daily for 12 weeks. In this post hoc analysis, spine MRIs were evaluated using the Canada-Denmark (CANDEN) MRI scoring system to assess changes from baseline to week 12 in total spine and subscores for inflammation, fat, erosion and new bone formation (NBF) at various anatomical locations. Correlations were assessed between CANDEN inflammation and clinical outcomes and Spondyloarthritis Research Consortium of Canada (SPARCC) MRI scores and between baseline CANDEN NBF and baseline BASFI and BASMI scores. RESULTS: MRIs from 47 filgotinib- and 41 placebo-treated patients were evaluated. There were significantly larger reductions with filgotinib vs placebo in total spine inflammation score and most inflammation subscores, including posterolateral elements (costovertebral joints, transverse/spinous processes, soft tissues), facet joints and vertebral bodies. No significant differences were observed for corner or non-corner vertebral body inflammation subscores, spine fat lesion, bone erosion or NBF scores. In the filgotinib group, the change from baseline in the total inflammation score correlated positively with the SPARCC spine score. Baseline NBF scores correlated with baseline BASMI but not BASFI scores. CONCLUSIONS: Compared with placebo, filgotinib treatment was associated with significant reductions in MRI measures of spinal inflammation, including in vertebral bodies, facet joints and posterolateral elements. TRIAL REGISTRATION: ClinicalTrials.gov (https://clinicaltrials.gov), NCT03117270.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Maksymowych WP, Østergaard M, Landewé R, et al. Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial. Rheumatology (Oxford). 2022. PMID: 34647992. doi:10.1093/rheumatology/keab758

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。